Researchers found that by December 2023, more than 1 in 3 of the medications being started for type 2 diabetes treatment were GLP-1RA-based medications.

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

When it comes to managing weight loss and type 2 diabetes with medications, research shows that it's out with the old and in with the new.

Pfizer has stopped developing a once-daily pill to treat obesity after a person in a clinical trial showed signs of a ...

When it comes to managing weight loss and type 2 diabetes with medications, research shows that it's out with the old and in ...

People who have tried other methods to lose weight have found results from obesity drugs that ‘feel like magic.’ ...

The drugmaker said it would stop studying danuglipron after a participant in one of its trials experienced a possible ...

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.

For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the ...

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper ...